Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jersey tax on cosmetic and large OP (outpatient) surgery ahead:

This article was originally published in Clinica

Executive Summary

New Jersey's state legislature has decided to tax certain surgical procedures as one way of bridging the state's budget gap. One bill that recently cleared both legislative chambers assesses a 6% gross receipts tax on cosmetic medical procedures, defined by the state as any procedures that do not meaningfully promote the proper functioning of the body or prevent or treat illness or disease. A second bill slaps a 3.5% gross receipts tax on ambulatory surgical centres, or outpatient (OP) surgery units that have gross receipts higher than $300,000. Although a coalition of medical groups is making a last-ditch effort to overturn the bills they describe as arbitrary and discriminatory, New Jersey Governor James McGreevey is expected to sign the legislation.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT058985

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel